PI3K δ Is a Therapeutic Target in Hepatocellular Carcinoma

Conclusion: Our data identify PI3K δ inhibition, recently approved for the treatment of human B‐cell malignancies, as a potential treatment for HCC.

Source: Hepatology - November 8, 2018 Category: Internal Medicine Authors: Eunkyong Ko, Hyun ‐Wook Seo, Eun Sun Jung, Soomi Ju, Baek‐hui Kim, Hyeki Cho, Yoon Jun Kim, Young Min Park, Jong‐Seo Kim, Guhung Jung Tags: Original Article Source Type: research